TECH
Bio-Techne Corporation
Biotechnology
Market Cap$7.42B
5Y Perf.-23.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TECH vs TMO
Revenue, margins, valuation, and 5-year total return — side by side.
TMO
Thermo Fisher Scientific Inc.
Medical - Diagnostics & Research
Market Cap$175.76B
5Y Perf.+37.2%
TECH vs TMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TECH | TMO |
|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $7.42B | $175.76B |
| Revenue (TTM) | $1.21B | $45.20B |
| Net Income (TTM) | $110M | $6.86B |
| Gross Margin | 65.0% | 39.4% |
| Operating Margin | 12.7% | 17.8% |
| Forward P/E | 25.7x | 19.0x |
| Total Debt | $444M | $40.85B |
| Cash & Equiv. | $162M | $9.86B |
TECH vs TMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TECH
TMO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Bio-Techne Corporat… (TECH) | 100 | 76.9 | -23.1% |
| Thermo Fisher Scien… (TMO) | 100 | 137.2 | +37.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TECH vs TMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TMO leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Bio-Techne Corporation is the stronger pick specifically for growth and revenue expansion and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
TECH
Bio-Techne Corporation
The Growth Play
TECH is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 5.2%, EPS growth -56.2%, 3Y rev CAGR 3.3%
- Lower volatility, beta 1.41, Low D/E 23.1%, current ratio 3.46x
- Beta 1.41, yield 0.7%, current ratio 3.46x
Best for: growth exposure and sleep-well-at-night
TMO
Thermo Fisher Scientific Inc.
The Income Pick
TMO carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 8 yrs, beta 1.10, yield 0.4%
- 229.1% 10Y total return vs TECH's 100.6%
- Lower P/E (19.0x vs 25.7x)
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TECH | 5.2% revenue growth vs TMO's 3.9% |
| Value | TMO | Lower P/E (19.0x vs 25.7x) |
| Quality / Margins | TMO | 15.2% margin vs TECH's 9.0% |
| Stability / Safety | TMO | Beta 1.10 vs TECH's 1.41 |
| Dividends | TECH | 0.7% yield, 3-year raise streak, vs TMO's 0.4% |
| Momentum (1Y) | TMO | +16.6% vs TECH's +0.0% |
| Efficiency (ROA) | TMO | 6.4% ROA vs TECH's 4.3%, ROIC 7.5% vs 3.4% |
TECH vs TMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
TECH vs TMO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTMOLAGGINGTECH
TECHBio-Techne Corporation
0leads
TMOThermo Fisher Scienti…
4leads
6 Total Categories
CATEGORYLEADERvs TECHMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
TMO6/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TMO5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
TMO6/6
Risk & VolatilityBeta, volatility, and downside exposure
TMO2/2
Analyst OutlookRatings, price targets, and dividends
Tied
—
Income & Cash Flow (Last 12 Months)
Evenly matched — TECH and TMO each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 37.3x TECH's $1.2B. TMO is the more profitable business, keeping 15.2% of every revenue dollar as net income compared to TECH's 9.0%. On growth, TMO holds the edge at +6.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | TECHBio-Techne Corpor… | TMOThermo Fisher Sci… |
|---|---|---|
| RevenueTrailing 12 months | $1.2B | $45.2B |
| EBITDAEarnings before interest/tax | $181M | $10.5B |
| Net IncomeAfter-tax profit | $110M | $6.9B |
| Free Cash FlowCash after capex | $270M | $6.7B |
| Gross MarginGross profit ÷ Revenue | +65.0% | +39.4% |
| Operating MarginEBIT ÷ Revenue | +12.7% | +17.8% |
| Net MarginNet income ÷ Revenue | +9.0% | +15.2% |
| FCF MarginFCF ÷ Revenue | +22.3% | +14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -1.5% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +128.6% | +11.3% |
Evenly matched — TECH and TMO each lead in 3 of 6 comparable metrics.
Valuation Metrics
TMO leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
At 26.7x trailing earnings, TMO trades at a 74% valuation discount to TECH's 103.1x P/E. On an enterprise value basis, TMO's 19.0x EV/EBITDA is more attractive than TECH's 36.3x.
| Metric | TECHBio-Techne Corpor… | TMOThermo Fisher Sci… |
|---|---|---|
| Market CapShares × price | $7.4B | $175.8B |
| Enterprise ValueMkt cap + debt − cash | $7.7B | $206.8B |
| Trailing P/EPrice ÷ TTM EPS | 103.05x | 26.66x |
| Forward P/EPrice ÷ next-FY EPS est. | 25.70x | 19.04x |
| PEG RatioP/E ÷ EPS growth rate | — | 12.62x |
| EV / EBITDAEnterprise value multiple | 36.29x | 18.99x |
| Price / SalesMarket cap ÷ Revenue | 6.08x | 3.94x |
| Price / BookPrice ÷ Book value/share | 3.95x | 3.33x |
| Price / FCFMarket cap ÷ FCF | 28.91x | 27.93x |
TMO leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
TMO leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
TMO delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $5 for TECH. TECH carries lower financial leverage with a 0.23x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMO's 0.76x. On the Piotroski fundamental quality scale (0–9), TMO scores 6/9 vs TECH's 5/9, reflecting solid financial health.
| Metric | TECHBio-Techne Corpor… | TMOThermo Fisher Sci… |
|---|---|---|
| ROE (TTM)Return on equity | +5.5% | +13.2% |
| ROA (TTM)Return on assets | +4.3% | +6.4% |
| ROICReturn on invested capital | +3.4% | +7.5% |
| ROCEReturn on capital employed | +4.2% | +9.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.23x | 0.76x |
| Net DebtTotal debt minus cash | $282M | $31.0B |
| Cash & Equiv.Liquid assets | $162M | $9.9B |
| Total DebtShort + long-term debt | $444M | $40.9B |
| Interest CoverageEBIT ÷ Interest expense | 38.20x | 5.89x |
TMO leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
TMO leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TMO five years ago would be worth $10,211 today (with dividends reinvested), compared to $4,769 for TECH. Over the past 12 months, TMO leads with a +16.6% total return vs TECH's +0.0%. The 3-year compound annual growth rate (CAGR) favors TMO at -4.2% vs TECH's -16.2% — a key indicator of consistent wealth creation.
| Metric | TECHBio-Techne Corpor… | TMOThermo Fisher Sci… |
|---|---|---|
| YTD ReturnYear-to-date | -20.4% | -20.1% |
| 1-Year ReturnPast 12 months | +0.0% | +16.6% |
| 3-Year ReturnCumulative with dividends | -41.2% | -11.9% |
| 5-Year ReturnCumulative with dividends | -52.3% | +2.1% |
| 10-Year ReturnCumulative with dividends | +100.6% | +229.1% |
| CAGR (3Y)Annualised 3-year return | -16.2% | -4.2% |
TMO leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
TMO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TMO is the less volatile stock with a 1.10 beta — it tends to amplify market swings less than TECH's 1.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TMO currently trades 73.4% from its 52-week high vs TECH's 65.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TECHBio-Techne Corpor… | TMOThermo Fisher Sci… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.41x | 1.10x |
| 52-Week HighHighest price in past year | $72.16 | $643.99 |
| 52-Week LowLowest price in past year | $45.12 | $385.46 |
| % of 52W HighCurrent price vs 52-week peak | +65.7% | +73.4% |
| RSI (14)Momentum oscillator 0–100 | 53.4 | 39.8 |
| Avg Volume (50D)Average daily shares traded | 2.3M | 1.9M |
TMO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Evenly matched — TECH and TMO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Wall Street rates TECH as "Buy" and TMO as "Buy". Consensus price targets imply 46.3% upside for TECH (target: $69) vs 38.4% for TMO (target: $655). For income investors, TECH offers the higher dividend yield at 0.67% vs TMO's 0.36%.
| Metric | TECHBio-Techne Corpor… | TMOThermo Fisher Sci… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $69.33 | $654.67 |
| # AnalystsCovering analysts | 25 | 42 |
| Dividend YieldAnnual dividend ÷ price | +0.7% | +0.4% |
| Dividend StreakConsecutive years of raises | 3 | 8 |
| Dividend / ShareAnnual DPS | $0.32 | $1.69 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.7% | +1.7% |
Evenly matched — TECH and TMO each lead in 1 of 2 comparable metrics.
Key Takeaway
TMO leads in 4 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 2 categories are tied.
Best OverallThermo Fisher Scientific In… (TMO)Leads 4 of 6 categories
Loading custom metrics...
TECH vs TMO: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is TECH or TMO a better buy right now?
For growth investors, Bio-Techne Corporation (TECH) is the stronger pick with 5.
2% revenue growth year-over-year, versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate Bio-Techne Corporation (TECH) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — TECH or TMO?
On trailing P/E, Thermo Fisher Scientific Inc.
(TMO) is the cheapest at 26. 7x versus Bio-Techne Corporation at 103. 1x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 19. 0x.
03Which is the better long-term investment — TECH or TMO?
Over the past 5 years, Thermo Fisher Scientific Inc.
(TMO) delivered a total return of +2. 1%, compared to -52. 3% for Bio-Techne Corporation (TECH). Over 10 years, the gap is even starker: TMO returned +229. 1% versus TECH's +112. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — TECH or TMO?
By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.
(TMO) is the lower-risk stock at 1. 10β versus Bio-Techne Corporation's 1. 41β — meaning TECH is approximately 29% more volatile than TMO relative to the S&P 500. On balance sheet safety, Bio-Techne Corporation (TECH) carries a lower debt/equity ratio of 23% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — TECH or TMO?
By revenue growth (latest reported year), Bio-Techne Corporation (TECH) is pulling ahead at 5.
2% versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). On earnings-per-share growth, the picture is similar: Thermo Fisher Scientific Inc. grew EPS 7. 3% year-over-year, compared to -56. 2% for Bio-Techne Corporation. Over a 3-year CAGR, TECH leads at 3. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — TECH or TMO?
Thermo Fisher Scientific Inc.
(TMO) is the more profitable company, earning 15. 1% net margin versus 6. 0% for Bio-Techne Corporation — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus 8. 4% for TECH. At the gross margin level — before operating expenses — TECH leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is TECH or TMO more undervalued right now?
On forward earnings alone, Thermo Fisher Scientific Inc.
(TMO) trades at 19. 0x forward P/E versus 25. 7x for Bio-Techne Corporation — 6. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TECH: 46. 3% to $69. 33.
08Which pays a better dividend — TECH or TMO?
All stocks in this comparison pay dividends.
Bio-Techne Corporation (TECH) offers the highest yield at 0. 7%, versus 0. 4% for Thermo Fisher Scientific Inc. (TMO).
09Is TECH or TMO better for a retirement portfolio?
For long-horizon retirement investors, Bio-Techne Corporation (TECH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0.
7% yield, +112. 5% 10Y return). Both have compounded well over 10 years (TECH: +112. 5%, TMO: +229. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between TECH and TMO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
TECH pays a dividend while TMO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(TECH: -1.5% · TMO: 6.2%)Net Margin>
%
(TECH: 9.0% · TMO: 15.2%)P/E Ratio<
x
(TECH: 103.1x · TMO: 26.7x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.